BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11429885)

  • 1. 3-amino-1,2,4-benzotriazine 4-oxide: characterization of a new metabolite arising from bioreductive processing of the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
    Fuchs T; Chowdhury G; Barnes CL; Gates KS
    J Org Chem; 2001 Jan; 66(1):107-14. PubMed ID: 11429885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase.
    Fitzsimmons SA; Lewis AD; Riley RJ; Workman P
    Carcinogenesis; 1994 Aug; 15(8):1503-10. PubMed ID: 8055626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward hypoxia-selective DNA-alkylating agents built by grafting nitrogen mustards onto the bioreductively activated, hypoxia-selective DNA-oxidizing agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
    Johnson KM; Parsons ZD; Barnes CL; Gates KS
    J Org Chem; 2014 Aug; 79(16):7520-31. PubMed ID: 25029663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
    Walton MI; Workman P
    J Pharmacol Exp Ther; 1993 May; 265(2):938-47. PubMed ID: 8496834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploiting the Inherent Photophysical Properties of the Major Tirapazamine Metabolite in the Development of Profluorescent Substrates for Enzymes That Catalyze the Bioreductive Activation of Hypoxia-Selective Anticancer Prodrugs.
    Shen X; Laber CH; Sarkar U; Galazzi F; Johnson KM; Mahieu NG; Hillebrand R; Fuchs-Knotts T; Barnes CL; Baker GA; Gates KS
    J Org Chem; 2018 Mar; 83(6):3126-3131. PubMed ID: 29461834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzymology of the reductive bioactivation of SR 4233. A novel benzotriazine di-N-oxide hypoxic cell cytotoxin.
    Walton MI; Workman P
    Biochem Pharmacol; 1990 Jun; 39(11):1735-42. PubMed ID: 2344370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1'-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions.
    Hwang JT; Greenberg MM; Fuchs T; Gates KS
    Biochemistry; 1999 Oct; 38(43):14248-55. PubMed ID: 10571998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of the cytotoxicity of the anticancer agent tirapazamine by benzotriazine N-oxides: the role of redox equilibria.
    Anderson RF; Shinde SS; Hay MP; Denny WA
    J Am Chem Soc; 2006 Jan; 128(1):245-9. PubMed ID: 16390153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidation of 2-deoxyribose by benzotriazinyl radicals of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides.
    Shinde SS; Anderson RF; Hay MP; Gamage SA; Denny WA
    J Am Chem Soc; 2004 Jun; 126(25):7865-74. PubMed ID: 15212534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidative DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
    Kotandeniya D; Ganley B; Gates KS
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2325-9. PubMed ID: 12161126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initiation of DNA strand cleavage by 1,2,4-benzotriazine 1,4-dioxide antitumor agents: mechanistic insight from studies of 3-methyl-1,2,4-benzotriazine 1,4-dioxide.
    Junnotula V; Sarkar U; Sinha S; Gates KS
    J Am Chem Soc; 2009 Jan; 131(3):1015-24. PubMed ID: 19117394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA base damage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
    Birincioglu M; Jaruga P; Chowdhury G; Rodriguez H; Dizdaroglu M; Gates KS
    J Am Chem Soc; 2003 Sep; 125(38):11607-15. PubMed ID: 13129365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
    Patterson AV; Barham HM; Chinje EC; Adams GE; Harris AL; Stratford IJ
    Br J Cancer; 1995 Nov; 72(5):1144-50. PubMed ID: 7577460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of cytochrome P450 and cytochrome P450 reductase in the reductive bioactivation of the novel benzotriazine di-N-oxide hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233, WIN 59075) by mouse liver.
    Walton MI; Wolf CR; Workman P
    Biochem Pharmacol; 1992 Jul; 44(2):251-9. PubMed ID: 1642640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical properties governing the hypoxia-selective cytotoxicity of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides.
    Anderson RF; Shinde SS; Hay MP; Gamage SA; Denny WA
    Org Biomol Chem; 2005 Jun; 3(11):2167-74. PubMed ID: 15917906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial characterization of the major mouse cytochrome P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR 4233, WIN 59075).
    Riley RJ; Hemingway SA; Graham MA; Workman P
    Biochem Pharmacol; 1993 Mar; 45(5):1065-77. PubMed ID: 8461036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mass spectrometry study of tirapazamine and its metabolites. insights into the mechanism of metabolic transformations and the characterization of reaction intermediates.
    Zagorevskii D; Song M; Breneman C; Yuan Y; Fuchs T; Gates KS; Greenlief CM
    J Am Soc Mass Spectrom; 2003 Aug; 14(8):881-92. PubMed ID: 12892912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of radicals formed following enzymatic reduction of 3-substituted analogues of the hypoxia-selective cytotoxin 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).
    Shinde SS; Maroz A; Hay MP; Patterson AV; Denny WA; Anderson RF
    J Am Chem Soc; 2010 Mar; 132(8):2591-9. PubMed ID: 20141134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia.
    Wang J; Foehrenbacher A; Su J; Patel R; Hay MP; Hicks KO; Wilson WR
    Clin Cancer Res; 2012 Mar; 18(6):1684-95. PubMed ID: 22167409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model.
    Kyle AH; Minchinton AI
    Cancer Chemother Pharmacol; 1999; 43(3):213-20. PubMed ID: 9923551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.